Media stories about NovaBay Pharmaceuticals (NYSE:NBY) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.7201252493924 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of NovaBay Pharmaceuticals (NYSE NBY) traded down 1.11% on Thursday, hitting $4.45. 1,757 shares of the company’s stock were exchanged. The firm’s market cap is $68.13 million. NovaBay Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $5.09. The stock’s 50 day moving average is $4.46 and its 200 day moving average is $3.81.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%. The company had revenue of $4.12 million for the quarter, compared to analyst estimates of $4.57 million. On average, equities analysts predict that NovaBay Pharmaceuticals will post ($0.47) earnings per share for the current year.

Several research firms have weighed in on NBY. Maxim Group reissued a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Friday, August 11th. HC Wainwright set a $6.00 price target on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Zacks Investment Research raised shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Finally, Roth Capital set a $6.00 price target on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, August 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $6.60.

WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Insider Buying and Selling by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)

Receive News & Stock Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.